Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41573-020-0082-8 http://scihub22266oqcxt.onion/10.1038/s41573-020-0082-8 33077936!7569567!33077936     free     free     free       Nat+Rev+Drug+Discov 2021 ; 20 (1): 39-63 Nephropedia Template TP {{tp|p=33077936|t=2021. Kinase inhibition in autoimmunity and inflammation |pdf=|usr=}}{{33077936}} gab.com Text Kinase inhibition in autoimmunity and inflammation JO: Nat Rev Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=33077936 #FOAvip Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet medical needs in some areas still exist. One of the main therapeutic approaches to alleviate dysregulated inflammation has been to target the activity of kinases that regulate production of inflammatory mediators. Small-molecule kinase inhibitors have the potential for broad efficacy, convenience and tissue penetrance, and thus often offer important advantages over biologics. However, designing kinase inhibitors with target selectivity and minimal off-target effects can be challenging. Nevertheless, immense progress has been made in advancing kinase inhibitors with desirable drug-like properties into the clinic, including inhibitors of JAKs, IRAK4, RIPKs, BTK, SYK and TPL2. This Review will address the latest discoveries around kinase inhibitors with an emphasis on clinically validated autoimmunity and inflammatory pathways. Twit Text FOAVip Kinase inhibition in autoimmunity and inflammation ????Nat Rev Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=33077936 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33077936 #FOAvip English Wikipedia <ref>{{Cite pmid|33077936}}</ref> Kinase inhibition in autoimmunity and inflammation #MMPMID33077936 Zarrin AA; Bao K; Lupardus P; Vucic D Nat Rev Drug Discov 2021[Jan]; 20 (1): 39-63 PMID33077936show ga Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet medical needs in some areas still exist. One of the main therapeutic approaches to alleviate dysregulated inflammation has been to target the activity of kinases that regulate production of inflammatory mediators. Small-molecule kinase inhibitors have the potential for broad efficacy, convenience and tissue penetrance, and thus often offer important advantages over biologics. However, designing kinase inhibitors with target selectivity and minimal off-target effects can be challenging. Nevertheless, immense progress has been made in advancing kinase inhibitors with desirable drug-like properties into the clinic, including inhibitors of JAKs, IRAK4, RIPKs, BTK, SYK and TPL2. This Review will address the latest discoveries around kinase inhibitors with an emphasis on clinically validated autoimmunity and inflammatory pathways. |Animals[MESH] |Autoimmune Diseases/*drug therapy/immunology/pathology[MESH] |Autoimmunity/*drug effects[MESH] |Humans[MESH] |Inflammation/*drug therapy/immunology/pathology[MESH] |Protein Kinase Inhibitors/*therapeutic use[MESH]Kinase inhibition in autoimmunity and inflammation (epmc).pdf DeepDyve Pubget Overpricing